EUCTR2020-002833-13-PL进行中（未招募）1 期
A Randomized, Placebo-controlled, Double-blind, Parallel-group, Exploratory, Phase 2 Study of the Efficacy and Safety of Oral AMT-101 in Combination with Adalimumab in Subjects with Moderate to Severe Ulcerative Colitis
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •The study will enroll male and female adult subjects with moderate to severe UC.
- •Inclusion criteria (subjects must meet the following criteria to be randomized into the study):
- •1. Male and female subjects aged 18 to 75 years, inclusive.
- •2. Diagnosis of UC for at least 3 months prior to screening.
- •3. Moderate to severe UC, as defined by a total MCS of 6 to 12 inclusive at baseline, with a MES = 2 (confirmed by central reader).
- •4. Eligible for adalimumab therapy.
- •5. Naïve to therapy with approved or investigational biologics/tofacitinib including any anti-tumor necrosis factor (TNF) therapy, vedolizumab, or ustekinumab.
- •6. If subjects are receiving the following treatments, they must be on a stable dose for at least 4 weeks prior to randomization:
- •a. 5-aminosalicylates (5-ASAs) (not exceeding 4.8 g per day).
- •b. Oral corticosteroids (not exceeding prednisone 20 mg, budesonide 9 mg, or equivalent).
- •c. 6-mercaptopurine (6-MP) (any stable dose).
- •d. Azathioprine (AZA) (any stable dose).
- •e. Methotrexate (MTX) (any stable dose).
- •Note: subjects may be using 5-ASA and only 1 of the other medications listed (oral corticosteroids/6 MP/AZA/MTX).
- •7. If subjects are receiving bile-salt sequestrant, they must be on a stable dose for at least 3 months prior to randomization.
- •8. If subjects are receiving any nonprohibited medications, they must agree to maintain stable doses of concomitant medications for UC until the end of the safety follow-up period.
- •9. Unlikely to conceive.
- •10. Women of childbearing potential (WOCBP) must have a negative pregnancy test at screening and at the randomization visit prior to the first dose of study drug.
- •11. Able to participate fully in all aspects of this clinical trial.
- •12. Written informed consent must be obtained and documented.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 25
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 5
排除标准
- •Exclusion criteria (subjects who exhibit any of the following criteria are to be excluded from the study):
- •1. A diagnosis of Crohn’s disease (CD), indeterminate colitis, or presence or history of fistula with CD.
- •2. Disease activity limited to distal 15 cm (proctitis).
- •3. Current evidence of toxic megacolon, abdominal abscess, symptomatic colonic stricture, or stoma.
- •4. History or current evidence of colonic dysplasia or adenomatous colonic polyps.
- •5. Current bacterial or parasitic pathogenic enteric infection, including Clostridium difficile;; known active cytomegalovirus infection; known infection with hepatitisB or C virus; known infection with human immunodeficiency virus; infection requiring hospitalization or intravenous (IV) antimicrobial therapy, or opportunistic infection within 6 months prior to screening; any infection requiring antimicrobial therapy within 2 weeks prior to screening; history of more than 1 episode of herpes zoster or any episode of disseminated zoster.
- •6. A positive diagnostic tuberculosis (TB) test at screening (defined as a positive QuantiFERON test). In cases where the QuantiFERON test is indeterminate, the participant may have the test repeated once and if their second test is negative, they will be eligible. In the event a second test is also indeterminate, or QuantiFERON is unavailable, the investigator has the option to perform a purified protein derivative (PPD) skin test. If the PPD reaction is < 5 mm, then the subject is eligible. If the reaction is = 5 mm, or PPD testing is not done, the subject is not eligible. An exception is made for subjects with a history of latent TB who are currently receiving treatment for latent TB, will initiate treatment for latent TB before the first dose of study treatment, or have documentation of completing appropriate treatment for latent TB within 3 years prior to the first dose of study treatment.
- •7. Live virus vaccination within 1 month prior to screening.
- •8. Any prior treatment with an approved or investigational biologic/tofacitinib, including anti-TNF therapy, vedolizumab, or ustekinumab.
- •9. Treatment with sirolimus, cyclosporine, mycophenolate, or tacrolimus within 8 weeks prior to randomization.
- •10. Treatment with IV corticosteroids, rectal corticosteroids, or rectal 5-ASA within 4 weeks prior to randomization.
- •11. Fecal microbiota transplantation within 1 month prior to screening.
- •12. A concurrent clinically significant, serious, unstable, or uncontrolled underlying cardiovascular, pulmonary, hepatic, renal, gastrointestinal, genitourinary, hematological, coagulation, immunological, endocrine/metabolic, or other medical disorder that, in the opinion of the investigator, might confound the study results, pose additional risk to the subject, or interfere with the subject’s ability to participate fully in the study.
- •13. A diagnosis of multiple sclerosis or optic neuritis, or history of a demyelinating disorder.
- •14. Known primary or secondary immunodeficiency.
- •15. History of myocardial infarction, unstable angina, transient ischemic attack, decompensated heart failure requiring hospitalization, congestive heart failure (New York Heart Association Class 3 or 4), uncontrolled arrhythmias, cardiac revascularization, stroke, uncontrolled hypertension, or uncontrolled diabetes within 6 months of screening.
- •16. Clinically meaningful laboratory abnormalities at screening that would affect subject safety, as determined and documented by the investigator.
- •17. Pregna
研究者
相似试验
进行中（未招募）
1 期
A study of AMT-101 in patients with Ulcerative Colitis.EUCTR2020-000047-31-BGApplied Molecular Transport Inc.102
进行中（未招募）
1 期
A study of AMT-101 in patients with Ulcerative Colitis.EUCTR2020-000047-31-PLApplied Molecular Transport Inc.102
进行中（未招募）
1 期
A study of AMT-101 in patients with Ulcerative Colitis.lcerative ColitisMedDRA version: 20.1Level: LLTClassification code 10045365Term: Ulcerative colitisSystem Organ Class: 100000004856EUCTR2020-000047-31-HUApplied Molecular Transport Inc.102
进行中（未招募）
1 期
A study of AMT-101 in patients with Ulcerative Colitis.lcerative ColitisMedDRA version: 20.1Level: LLTClassification code 10045365Term: Ulcerative colitisSystem Organ Class: 100000004856EUCTR2020-000047-31-GBApplied Molecular Transport Inc.102
进行中（未招募）
1 期
A study of AMT-101 in patients with Ulcerative Colitis.lcerative ColitisMedDRA version: 20.1Level: LLTClassification code 10045365Term: Ulcerative colitisSystem Organ Class: 100000004856EUCTR2020-000047-31-FRApplied Molecular Transport Inc.102